To address these limitations, we investigated whether TIM-3 blockade could mitigate CD8+ T cells exhaustion during OVV therapy, demonstrating that this combinatorial approach not only proves clinically feasible but also synergistically enhances anti-tumor immunity through TME remodeling. Here, HAVCR2 is linked to neoplasm.